Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Next Previous
X
Search
Trial Profile

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonapegsomatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Registrational
  • Acronyms fliGHt
  • Sponsors Ascendis Pharma

    • Most Recent Events

    • 18 Jun 2023 Results assessing explores IGF-1 levels, dose adjustments, and height outcomes by Tanner Stage in 3 studies heiGHt (treatment-naive trial), fliGHt (switch trial), and enliGHten (open-label extension trial), presented at the 105th Annual Meeting of the Endocrine Society.
    • 13 Jun 2023 According to an Ascendis Pharma media release, the poster including the subanalysis of tanner stage in children and adolescents with growth hormone deficiency treated with lonapegsomatropin will be presented at ENDO 2023, the annual meeting of the Endocrine Society being held June 15-18 in Chicago.
    • 12 Nov 2021 According to an Ascendis Pharma media release, European Medicine Agencys Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization for Lonapegsomatropin .The European Commission final decision on the Companys MAA for TransCon hGH is expected within 67 days after the positive opinion, or by the end of January 2022.The CHMP opinion is based on results submitted in the MAA from heiGHt, fliGHt and enlighten.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top